Shanghai Jiao Tong University School of Medicine: Breast Neoplasms trials

The registry lists 22 Breast Neoplasms studies with Shanghai Jiao Tong University School of Medicine as lead sponsor. 11 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 11Phase 3 3Phase 4 2No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Artificial Intelligence (AI)-Based Personalized Exercise Coaching for Patients With Breast CancerRecruitingNCT07844941Not applicable
• Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCRecruitingNCT07797218Phase 3
• Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerRecruitingNCT07393425Phase 2
• Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast CancerRecruitingNCT07371208Phase 2
• ctDNA in HER2+ EBC Neoadjuvant TreatmentRecruitingNCT07335081Phase 2
• GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast CancerRecruitingNCT06725940
• Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BCRecruitingNCT06500208Phase 2
• Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer PatientsNot yet recruitingNCT05901025
• Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast CancerRecruitingNCT05891561Phase 2
• Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast CancerNot yet recruitingNCT05843292Phase 4
• A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of BreastRecruitingNCT02897700Phase 1
• MRD in High-risk EBCActive, not recruitingNCT06566729
• RJBC-APP and Breast Cancer Treatment ComplianceCompletedNCT05921331Not applicable
• Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerActive, not recruitingNCT04398914Phase 2
• Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerTerminatedNCT04066790Phase 2
• Decitabine Plus Carboplatin in the Treatment of Metastatic TNBCTerminatedNCT03295552Phase 2
• Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine TherapyCompletedNCT02455154Phase 2
• Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast CancerActive, not recruitingNCT02455141Phase 3
• Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer PatientsCompletedNCT02440230Phase 2
• Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast CancerCompletedNCT02344940Phase 4
• Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast CancerCompletedNCT01203267Phase 2
• Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast CancerTerminatedNCT00912444Phase 3